Advertisement

SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia

      Highlights

      • SAFEHEART-risk equation can now be used in other European population of HeFH patients to predict CV events.
      • The cholesterol-year-score is a robust predictor of CV events in HeFH patients.
      • SAFEHEART-RE and the cholesterol-year-score are valid in primary prevention heFH patients.

      Abstract

      Background and aims

      Patients with heterozygous familial hypercholesterolemia (HeFH) present elevated cardiovascular (CV) risk. Current CV risk stratification algorithms developed for the general population are not adapted for heFH patients. It is therefore of singular importance to develop and validate CV prediction tools, which are dedicated to the HeFH population.

      Methods

      Our first objective was to validate the Spanish SAFEHEART-risk equation (RE) in the French HeFH cohort (REFERCHOL), and the second to compare SAFEHEART-RE with the low-density-lipoprotein-cholesterol (LDL-C)-year-score for the prediction of CV events in the HeFH French population.

      Results

      We included HeFH (n = 1473) patients with a genetic or clinical diagnosis (DLCN score ≥8). Among them, 512 patients with a 5-year follow-up were included to validate the 5 year-CV-RE. A total of 152 events (10.3%) occurred in the entire population of 1473 patients during a mean follow-up of 3.9 years. Over the five-year follow-up, non-fatal CV events occurred in 103 patients (20.2%). Almost all the parameters used in the SAFEHEART-RE were confirmed as strong predictors of CV events in the REFERCHOL cohort. The C-statistic revealed a satisfactory performance of both the SAFEHEART-RE and LDL-C-year-scores in predicting CV events for all the patients (primary and secondary prevention) (C-index 0.77 and 0.70, respectively) as well as for those in primary prevention at inclusion (C-index 0.78 and 0.77, respectively).

      Conclusions

      This analysis represents the first external validation of the SAFEHEART-RE and demonstrated that both SAFEHEART-RE and the LDL-C-year-score are good predictors of CV events in primary prevention HeFH patients.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nordestgaard B.G.
        • Chapman M.J.
        • Humphries S.E.
        • Ginsberg H.N.
        • Masana L.
        • Descamps O.S.
        • et al.
        Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.
        Eur. Heart J. 2013 Dec; 34 (3478-90a)
        • Benn M.
        • Watts G.F.
        • Tybjaerg-Hansen A.
        • Nordestgaard B.G.
        Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.
        J. Clin. Endocrinol. Metab. 2012 Nov; 97: 3956-3964
        • Benedek P.
        • Eriksson M.
        • Duvefelt K.
        • Freyschuss A.
        • Frick M.
        • Lundman P.
        • et al.
        Genetic testing for familial hypercholesterolemia among survivors of acute coronary syndrome.
        J. Intern. Med. 2018 Dec; 284: 674-684
        • Mundal L.
        • Igland J.
        • Ose L.
        • Holven K.B.
        • Veierod M.B.
        • Leren T.P.
        • et al.
        Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013.
        Eur. J. Prev. Cardiol. 2017 Jan; 24: 137-144
        • Beliard S.
        • Millier A.
        • Carreau V.
        • Carrie A.
        • Moulin P.
        • Fredenrich A.
        • et al.
        The very high cardiovascular risk in heterozygous familial hypercholesterolemia: analysis of 734 French patients.
        J. Clin. Lipidol. 2016 Sep-Oct; 10: 1129-11236 e3
        • Santos R.D.
        • Gidding S.S.
        • Hegele R.A.
        • Cuchel M.A.
        • Barter P.J.
        • Watts G.F.
        • et al.
        Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.
        Lancet Diabetes Endocrinol. 2016 Oct; 4: 850-861
        • Sniderman A.D.
        • Tsimikas S.
        • Fazio S.
        The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies.
        J. Am. Coll. Cardiol. 2014 May 20; 63: 1935-1947
        • Mach F.
        • Baigent C.
        • Catapano A.L.
        • Koskinas K.C.
        • Casula M.
        • Badimon L.
        • et al.
        ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
        Eur. Heart J. 2019; 41 (2019 Aug 31): 111-188
        • Santos R.D.
        • Gidding S.S.
        • Hegele R.A.
        • Cuchel M.A.
        • Barter P.J.
        • Watts G.F.
        • et al.
        Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.
        Lancet Diabetes Endocrinol. 2016 Oct; 4: 850-861
        • Perez de Isla L.
        • Alonso R.
        • Mata N.
        • Fernandez-Perez C.
        • Muniz O.
        • Diaz-Diaz J.L.
        • et al.
        Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish familial hypercholesterolemia cohort study).
        Circulation. 2017 May 30; 135: 2133-2144
        • Mata P.
        • Alonso R.
        • Perez de Isla L.
        Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?.
        Curr. Opin. Lipidol. 2018 Dec; 29: 445-452
        • Schmidt H.H.
        • Hill S.
        • Makariou E.V.
        • Feuerstein I.M.
        • Dugi K.A.
        • Hoeg J.M.
        Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia.
        Am. J. Cardiol. 1996 Mar 15; 77: 575-580
        • Gallo A.
        • Giral P.
        • Carrie A.
        • Carreau V.
        • Beliard S.
        • Bittar R.
        • et al.
        Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia.
        J. Clin. Lipidol. 2017 May - Jun; 11: 704-711 e2
        • Beliard S.
        • Boccara F.
        • Cariou B.
        • Carrie A.
        • Collet X.
        • Farnier M.
        • et al.
        High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: the French Familial Hypercholesterolemia Registry.
        Atherosclerosis. 2018 Oct; 277: 334-340
        • Law M.R.
        • Wald N.J.
        • Rudnicka A.R.
        Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
        BMJ. 2003 Jun 28; 326: 1423
        • Hicks K.A.
        • Mahaffey K.W.
        • Mehran R.
        • Nissen S.E.
        • Wiviott S.D.
        • Dunn B.
        • et al.
        Cardiovascular and stroke endpoint definitions for clinical trials.
        J. Am. Coll. Cardiol. 2017; 71 (2018 Mar 6): 1021-1034
        • Collins G.S.
        • Reitsma J.B.
        • Altman D.G.
        • Moons K.G.
        Transparent reporting of a multivariable prediction model for individual Prognosis or diagnosis (TRIPOD).
        Ann. Intern. Med. 2015 May 19; 162: 735-736
        • D'Agostino Sr., RB
        • Vasan R.S.
        • Pencina M.J.
        • Wolf P.A.
        • Cobain M.
        • Massaro J.M.
        • et al.
        General cardiovascular risk profile for use in primary care: the Framingham Heart Study.
        Circulation. 2008 Feb 12; 117: 743-753
        • Civeira F.
        • Castillo S.
        • Alonso R.
        • Merino-Ibarra E.
        • Cenarro A.
        • Artied M.
        • et al.
        Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation.
        Arterioscler. Thromb. Vasc. Biol. 2005 Sep; 25: 1960-1965
        • Tada H.
        • Kawashiri M.A.
        • Nohara A.
        • Inazu A.
        • Mabuchi H.
        • Yamagishi M.
        Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia.
        Eur. Heart J. 2017 May 21; 38: 1573-1579
        • Hoeg J.M.
        • Feuerstein I.M.
        • Tucker E.E.
        Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia.
        Arterioscler. Thromb. 1994 Jul; 14: 1066-1074
        • Luirink I.K.
        • Wiegman A.
        • Kusters D.M.
        • Hof M.H.
        • Groothoff J.W.
        • de Groot E.
        • et al.
        20-Year follow-up of statins in children with familial hypercholesterolemia.
        N. Engl. J. Med. 2019 Oct 17; 381: 1547-1556
        • Kusters D.M.
        • Wiegman A.
        • Kastelein J.J.
        • Hutten B.A.
        Carotid intima-media thickness in children with familial hypercholesterolemia.
        Circ. Res. 2014 Jan 17; 114: 307-310
        • Den Ruijter H.M.
        • Peters S.A.
        • Anderson T.J.
        • Britton A.R.
        • Dekker J.M.
        • Eijkemans M.J.
        • et al.
        Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis.
        J. Am. Med. Assoc. 2012 Aug 22; 308: 796-803
        • Miname M.H.
        • Bittencourt M.S.
        • Pereira A.C.
        • Jannes C.E.
        • Krieger J.E.
        • Nasir K.
        • et al.
        Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia.
        Eur. Heart J. Cardiovasc. Imag. 2019 Nov 8; 12: 1797-1804
        • Perez de Isla L.
        • Alonso R.
        • Muniz-Grijalvo O.
        • Diaz-Diaz J.L.
        • Zambon D.
        • Miramontes J.P.
        • et al.
        Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study.
        J. Clin. Lipidol. 2018 Jul - Aug; 12: 948-957
        • Chiva-Blanch G.
        • Padro T.
        • Alonso R.
        • Crespo J.
        • Perez de Isla L.
        • Mata P.
        • et al.
        Liquid biopsy of extracellular microvesicles maps coronary calcification and atherosclerotic plaque in asymptomatic patients with familial hypercholesterolemia.
        Arterioscler. Thromb. Vasc. Biol. 2019 May; 39: 945-955
        • Ellis K.L.
        • Perez de Isla L.
        • Alonso R.
        • Fuentes F.
        • Watts G.F.
        • Mata P.
        Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia.
        J. Am. Coll. Cardiol. 2019 Mar 12; 73: 1029-1039
        • Perrot N.
        • Theriault S.
        • Dina C.
        • Chen H.Y.
        • Boekholdt S.M.
        • Rigade S.
        • et al.
        Genetic variation in LPA, calcific aortic valve stenosis in patients undergoing cardiac surgery, and familial risk of aortic valve microcalcification.
        JAMA Cardiol. 2019 Jul 1; 4: 620-627
        • Zewinger S.
        • Kleber M.E.
        • Tragante V.
        • McCubrey R.O.
        • Schmidt A.F.
        • Direk K.
        • et al.
        Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.
        Lancet Diabetes Endocrinol. 2017 Jul; 5: 534-543
        • Ference B.A.
        • Ginsberg H.N.
        • Graham I.
        • Ray K.K.
        • Packard C.J.
        • Bruckert E.
        • et al.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
        Eur. Heart J. 2017 Aug 21; 38: 2459-2472
        • Marston N.A.
        • Kamanu F.K.
        • Nordio F.
        • Gurmu Y.
        • Roselli C.
        • Sever P.S.
        • et al.
        Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER trial.
        Circulation. 2019 Nov 11; 41: 616-623